New Delhi. On November 9, 2026, the central government had fixed the prices of 137 medicines used in the treatment of cancer. After this there has been a big decline in the prices of these medicines. Due to the steps taken by the Central Government, more than Rs 3500 crore will be saved every year in the treatment of cancer patients. The expert committee of the Directorate General of Health Services had recommended on October 17 to reduce the price of cancer medicines. According to the latest information, the prices of the medicines which are about to be launched will also fall.
A release from the Ministry of Chemicals and Fertilizers said that the National Pharmaceutical Pricing Authority (NPPA) has imposed margin limits on 137 cancer-related drugs. Till now, 76 companies manufacturing cancer medicines have fixed the new MRP for 1225 formulations of 121 medicines. Of these, the price of 1031 formulations has been reduced. Due to which the prices of 600 brands have been reduced by more than 50 percent. The maximum reduction in cancer medicines was found to be 96.45 percent.
The price of RPG Life Sciences' Palbopro medicine has become Rs 2720 instead of Rs 40421.33. This medicine is used in the treatment of breast cancer. Similarly, the price of Zydus Lifesciences' Brixta has now been increased to Rs 3318. The earlier price of this medicine, which is used in lung and cervical cancer, was Rs 25995. At the same time, the price of Arvincare Pharma's Abiron has increased from Rs 41250 to Rs 3218.23. This medicine is for prostate cancer. Similarly, Reliance Lifesciences' Denosteorel medicine will now be available for Rs 6240 instead of Rs 24955. Whereas, the price of Lupiher-2 Injection of Lupine Limited has decreased from Rs 83520 to Rs 37358.30. Lupiher-2 Injection is used in the treatment of breast cancer. Along with getting information about the new price of the medicine, one can also complain about violation of rules through NPPA portal or Pharma Sahi Daam app.